Abstract | BACKGROUND: METHODS: RESULTS: CONCLUSION: The overall safety profile of buparlisib remained unchanged, and no new or unexpected safety findings were reported in this study. Preliminary assessment for both combinations did not demonstrate sufficient antitumour activity compared with historical data on single-agent carboplatin or lomustine. TRIAL REGISTRATION NUMBER: NCT01934361.
|
Authors | Mark Rosenthal, Paul M Clement, Mario Campone, Miguel J Gil-Gil, John DeGroot, Olivier Chinot, Ahmed Idbaih, Hui Gan, Jeffrey Raizer, Patrick Yung Wen, Estela Pineda, Valerie Donnet, David Mills, Mona El-Hashimy, Warren Mason |
Journal | ESMO open
(ESMO Open)
Vol. 5
Issue 4
(07 2020)
ISSN: 2059-7029 [Electronic] England |
PMID | 32665311
(Publication Type: Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | © Author (s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology. |
Chemical References |
- Aminopyridines
- Morpholines
- NVP-BKM120
- Lomustine
- Carboplatin
|
Topics |
- Aged
- Aminopyridines
- Antineoplastic Combined Chemotherapy Protocols
- Bayes Theorem
- Carboplatin
(therapeutic use)
- Female
- Glioblastoma
(drug therapy)
- Humans
- Lomustine
(therapeutic use)
- Male
- Middle Aged
- Morpholines
- Phosphatidylinositol 3-Kinases
(therapeutic use)
- Recurrence
|